Description
What it is
A research blend pairing the FDA-approved GHRH analog Tesamorelin with the selective GH-releaser Ipamorelin — targeting both arms of the GH axis simultaneously.
Why it’s studied
The combination stimulates GHRH receptors (via Tesamorelin) and ghrelin receptors (via Ipamorelin) in parallel, a dual-receptor approach well-documented for amplifying IGF-1 response.
Key research findings
-
Tesamorelin: 15-18% reduction in visceral adipose tissue at 26 weeks (Falutz et al.)
-
Ipamorelin: clean GH release without cortisol/prolactin (Raun et al.)
-
Dual-receptor stimulation documented to amplify IGF-1 response beyond either alone
